{"id":"W3179641925","doi":"10.1007/s10637-021-01146-x","title":"A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer","year":2021,"lang":"en","type":"article","venue":"Investigational New Drugs","topic":"Fibroblast Growth Factor Research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":28,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Medicine; Tolerability; Adverse effect; Internal medicine; Toxicity; Cancer; Radioimmunotherapy; Antibody-drug conjugate; Phases of clinical research; Gastroenterology; Antibody; Oncology; Pharmacology; Monoclonal antibody; Immunology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009798034,0.0002710528,0.0003374959,0.0001303903,0.0000580878,0.00003189125,0.000239539,0.00005986718,0.0003110197],"category_scores_gemma":[0.0003564015,0.0002239066,0.00005575422,0.0005785924,0.0001673899,0.00003490509,0.000145746,0.0001760063,0.000009608563],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005767285,"about_ca_system_score_gemma":0.001436763,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003370841,"about_ca_topic_score_gemma":0.0005246661,"domain_scores_codex":[0.9977372,0.0002055629,0.0004698228,0.0005885918,0.0006545705,0.0003443047],"domain_scores_gemma":[0.9985889,0.00007377507,0.0001996432,0.000317073,0.0005627714,0.0002578618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002876147,0.003829302,0.1722292,0.0002644044,0.0004178784,0.00002172288,0.001940113,0.0004864502,0.814694,0.0000688008,0.002181931,0.0009900193],"study_design_scores_gemma":[0.04078425,0.006244858,0.1736731,0.0006708719,0.00005937357,0.000005769848,0.001312702,0.00009533813,0.7747881,0.0001980079,0.001282296,0.0008853256],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983388,0.00009466572,0.00003723483,0.0002639594,0.00005642668,0.0007428507,0.0004148409,0.00001142887,0.00003982301],"genre_scores_gemma":[0.995814,0.00001758193,0.002300703,0.000148508,0.00005935795,0.00007511178,0.0008388482,0.00004640168,0.0006995138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03990586,"threshold_uncertainty_score":0.9130645,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01728077159289466,"score_gpt":0.3150924209845254,"score_spread":0.2978116493916308,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}